Acute Respiratory Distress Syndrome (ARDS) Treatment Market Intelligence Size, Share, Forecast & Industry Analysis

DataM Intelligence unveils its latest report on the "Acute Respiratory Distress Syndrome Treatment Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies aiming to stay ahead in the competitive Market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/acute-respiratory-distress-syndrome-treatment-market?kb

M&A and Investments

In August 2023, Athersys signed a memorandum of understanding with Healios for the global license of MultiStem cell therapy in ARDS, including $6 million in near-term payments and up to $150 million in milestones and royalties to support development and commercialization.

Government and private sector funding for critical care medicine R&D, specifically in ARDS, increased following the COVID-19 pandemic, fostering new therapeutic candidates and solutions

List of Top Key Player:

AbbVie Inc., Pfizer Inc., Par Pharmaceutical Inc., Merit Pharmaceutical, Narang Medical Limited, Beijing Aeonmed Co. Ltd., Shenzhen Mindray Bio-Medical Electronic Co. Ltd, Medtronic Plc., Drägerwerk AG & Co. KGaA and ONY Biotech Inc among others.

Industry Developments:

In September 2023, Chrysalis received FDA approval to begin clinical trials of Chrysalin (TP508), a regenerative peptide that speeds tissue repair, revascularization, and modulates inflammation. ARDS incidence in the U.S. ranges from 64.2-78.9 cases per 100,000 person-years, with 25% mild and 75% moderate-to-severe cases. In July 2023, Aqualung Therapeutics got FDA clearance for the P2A PUERTA Study in moderate/severe ARDS patients, supporting regional market growth. Globally, sepsis caused 11 million deaths in 2023, with children under 5 accounting for nearly 3 million, highlighting sepsis as a leading ARDS trigger.

Forecast Projection:

The Global Acute Respiratory Distress Syndrome Treatment Market is poised for significant growth between 2025 and 2032. In 2024, the market maintained a steady upward trajectory, and with strategic initiatives by leading players accelerating adoption, the market is expected to soar throughout the forecast period. Companies leveraging these trends are well-positioned to capture emerging opportunities and maximize revenue potential.

Market Intelligence Research Process:

The Acute Respiratory Distress Syndrome Treatment Market research report by DataM Intelligence combines primary and secondary data to deliver deep, actionable insights. It examines the full spectrum of factors shaping the industry, from government regulations and market conditions to competitive dynamics, historical trends, technological breakthroughs, upcoming innovations, and potential challenges. This comprehensive analysis not only highlights growth prospects but also identifies barriers, equipping businesses to navigate market volatility and capitalize on emerging opportunities.

News:

The ARDS market is projected to grow from around $1.32 billion in 2024 to $2.53 billion by 2033, at a CAGR of 7.5%, fueled by rising demand for advanced respiratory support devices, oxygen therapy innovations, and new drug developments.

Integration of artificial intelligence and standardized medical protocols is improving ARDS management, allowing more personalized care and accurate disease progression predictions.

Clinical research is actively exploring stem cell and monoclonal antibody therapies. Products such as MultiStem (Athersys/Healios), EB05 (Edesa Biotech), ExoFlo (Direct Biologics), and ALT-100 (Aqualung Therapeutics) are progressing through Phase II/III global trials, with Fast Track designations in the U.S. and Japan.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=acute-respiratory-distress-syndrome-treatment-market

Key Segmentation:

By Treatment: (Drug Class, Device)

By Route of Administration: (Oral, Parenteral)

By Sales Channel: (Distribution Channel, End User)

Global Growth Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1 - Market Overview: Kickstarts the report with a comprehensive snapshot of the Acute Respiratory Distress Syndrome Treatment Market, summarizing key segments by region, product type, and application. Highlights include market size, segment growth potential, and short- & long-term industry outlook.

Chapter 2 - Emerging Trends: Uncovers the game-changing trends and high-impact innovations shaping the future of the industry.

Chapter 3 - Competitive Landscape: Offers a deep dive into market competition, detailing revenue shares, strategic initiatives, and recent mergers & acquisitions.

Chapter 4 - Top Player Profiles: Features detailed company profiles, covering revenue, profit margins, product lines, and major milestones for leading market players.

Chapters 5 & 6 - Regional & Country Analysis: Breaks down revenue performance across global regions, providing insights on market sizes, opportunities, and growth prospects worldwide.

Chapter 7 - Segmentation Analysis: Explores market segmentation by type, revealing high-potential categories and guiding businesses towards lucrative areas.

Chapter 8 - Application Insights: Examines downstream markets and identifies promising sectors for expansion, showing how different applications are driving growth.

Chapter 9 - Supply Chain Mapping: Maps the entire industry supply chain, highlighting upstream and downstream activities for a holistic market perspective.

Chapter 10 - Key Takeaways: Concludes with critical insights and actionable strategies, equipping stakeholders to make informed decisions and stay ahead in the market.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/acute-respiratory-distress-syndrome-treatment-market?kb

FAQ's

Q1: How fast is the Acute Respiratory Distress Syndrome Treatment Market expected to grow in the coming years?

A: The market is forecast to expand at a robust High CAGR between 2025 and 2032, signaling strong global growth and investment potential.

Q2: Which regions are dominating the Acute Respiratory Distress Syndrome Treatment Market and which are fastest-growing?

A: North America dominating the Acute Respiratory Distress Syndrome Treatment market.

Product and Therapy Launches

Several ARDS therapies are in late-stage trials with upcoming launch potential:

EB05 (paridiprubart, Edesa Biotech/Light Chain Bio): Granted US FDA Fast Track designation, currently in Phase III.

MultiStem cell therapy (Athersys/Healios): In pivotal Phase II/III trials for COVID-related and other ARDS, holding Breakthrough and Orphan Drug designations.

ExoFlo (Direct Biologics) & ALT-100 (Aqualung Therapeutics): Both in advanced development, featuring novel approaches to reduce inflammation and support lung recovery.

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.